My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1175

    1.

    Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

    Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

    Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.

    Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS.

    J Clin Endocrinol Metab. 2003 Nov;88(11):5248-54.PMID: 14602757 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

    Gribble FM, Manley SE, Levy JC.

    Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

    Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

    Diabetes Care. 2001 Jun;24(6):983-8.PMID: 11375357 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.

    Barnett AH, Anderson DM, Shelley S, Morgan R, Owens DR.

    Diabetes Obes Metab. 2004 Mar;6(2):104-13.PMID: 14746575 [PubMed - indexed for MEDLINE]Related articles

    6.

    Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.

    Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.

    Diabetes Care. 2006 Feb;29(2):189-94.PMID: 16443858 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

    Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

    8.

    Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

    Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

    Clin Ther. 2000 Feb;22(2):222-30.PMID: 10743981 [PubMed - indexed for MEDLINE]Related articles

    9.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.

    Diabetes Care. 1997 Apr;20(4):597-606.PMID: 9096986 [PubMed - indexed for MEDLINE]Related articles

    11.

    Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

    Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD.

    Diabetes Care. 1997 Oct;20(10):1539-42.PMID: 9314631 [PubMed - indexed for MEDLINE]Related articles

    12.

    Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

    Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

    Diabetes Care. 2003 Jun;26(6):1685-90.PMID: 12766094 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

    Diabetes. 2001 Aug;50(8):1778-84.PMID: 11473038 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.

    Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S.

    Acta Diabetol. 2000 Mar;37(1):41-6.PMID: 10928235 [PubMed - indexed for MEDLINE]Related articles

    15.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    16.

    A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.

    Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS.

    JAMA. 1998 Jan 14;279(2):137-43.PMID: 9440664 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.

    Ahmed AB, Home PD.

    Diabetes Care. 1998 Jan;21(1):32-7.PMID: 9538967 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

    Horton ES, Foley JE, Shen SG, Baron MA.

    Curr Med Res Opin. 2004 Jun;20(6):883-9.PMID: 15200747 [PubMed - indexed for MEDLINE]Related articles

    19.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.

    Luzio SD, Anderson DM, Owens DR.

    J Clin Endocrinol Metab. 2001 Oct;86(10):4874-80.PMID: 11600556 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity